0.3238
Applied Therapeutics Inc stock is traded at $0.3238, with a volume of 13.28M.
It is down -14.79% in the last 24 hours and down -15.63% over the past month.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
See More
Previous Close:
$0.38
Open:
$0.3792
24h Volume:
13.28M
Relative Volume:
6.36
Market Cap:
$54.66M
Revenue:
-
Net Income/Loss:
$-119.76M
P/E Ratio:
-0.2399
EPS:
-1.35
Net Cash Flow:
$-55.17M
1W Performance:
-5.57%
1M Performance:
-15.63%
6M Performance:
-62.05%
1Y Performance:
-92.96%
Applied Therapeutics Inc Stock (APLT) Company Profile
Name
Applied Therapeutics Inc
Sector
Industry
Phone
212-220-9226
Address
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
Compare APLT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
APLT
Applied Therapeutics Inc
|
0.3238 | 54.66M | 0 | -119.76M | -55.17M | -1.35 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-23-24 | Downgrade | William Blair | Outperform → Mkt Perform |
Dec-02-24 | Downgrade | UBS | Buy → Neutral |
Nov-29-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Jul-31-24 | Initiated | William Blair | Outperform |
Mar-26-24 | Initiated | RBC Capital Mkts | Outperform |
Feb-22-24 | Initiated | Leerink Partners | Outperform |
Jan-04-22 | Downgrade | Barclays | Overweight → Equal Weight |
Aug-27-21 | Downgrade | Goldman | Neutral → Sell |
Jun-25-21 | Resumed | Goldman | Neutral |
Oct-08-20 | Initiated | Truist | Buy |
Apr-22-20 | Initiated | Goldman | Buy |
Feb-27-20 | Initiated | Barclays | Overweight |
Jun-10-19 | Initiated | Citigroup | Buy |
Jun-10-19 | Initiated | Cowen | Outperform |
Jun-10-19 | Initiated | Robert W. Baird | Outperform |
View All
Applied Therapeutics Inc Stock (APLT) Latest News
Applied Therapeutics promotes two executives to leadership roles By Investing.com - Investing.com South Africa
Applied Therapeutics Announces New Chief Medical Officer - TipRanks
APLT Announces Key Executive Promotions | APLT Stock News - GuruFocus
Applied Therapeutics Promotes Evan Bailey to Chief Medical Officer - MarketScreener
Applied Therapeutics Announces Key Leadership Appointments | APLT Stock News - GuruFocus
Applied Therapeutics promotes two executives to leadership roles - Investing.com
Applied Therapeutics Announces Key Leadership Appointments - GlobeNewswire
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New Investment in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
California State Teachers Retirement System Purchases 64,316 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Applied Therapeutics holds annual stockholders meeting By Investing.com - Investing.com Canada
Applied Therapeutics Elects New Director at Annual Meeting - TipRanks
Applied Therapeutics holds annual stockholders meeting - Investing.com
Two Sigma Investments LP Buys New Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Applied Therapeutics, Inc. (NASDAQ:APLT) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Set Applied Therapeutics, Inc. (NASDAQ:APLT) Target Price at $6.10 - Defense World
Wellington Management Group LLP Boosts Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Applied Therapeutics, Inc. (NASDAQ:APLT) Shares Acquired by Millennium Management LLC - MarketBeat
Shareholder Rights Advocates at Levi & Korsinsky Investigate Applied Therapeutics, Inc. (APLT) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Applied Therapeutics, Inc. (NASDAQ:APLT) Short Interest Update - MarketBeat
Millennium Management LLC Boosts Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Class Action Filed Against Applied Therapeutics, Inc. (APLT)February 18, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics, Inc. LawsuitAPLT - ACCESS Newswire
Shareholders of Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire
BNP Paribas Financial Markets Grows Stake in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Janus Henderson Group PLC Sells 10,505,737 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Columbia Trustee Got Sued for Securities Fraud — Then Left Her Pharma Firm Under a Cloud - The Intercept
Janus Henderson Group PLC Decreases Stake in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Price T Rowe Associates Inc. MD Sells 986,108 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
William Blair Brokers Increase Earnings Estimates for APLT - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
Vestal Point Capital LP Acquires 10,355,000 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Stock Rating Upgraded by Wall Street Zen - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Applied Therapeutics Inc (APLT): An Important Analyst Insights - Stocksregister
Applied Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire
Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug - MSN
Applied Therapeutics’ Rare Disease Treatment Flunks in Late-Stage Trial - NewsBreak: Local News & Alerts
New top-line data from Phase II/III trial of govorestat in CMT-SORD - The Pharma Letter
Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug By Stocktwits - Investing.com India
Applied Therapeutics Presents Full 12-Month Clinical Results and - GuruFocus
APLT Shares Results from INSPIRE Trial on Govorestat at Peripher - GuruFocus
APLT Shares Results from INSPIRE Trial on Govorestat at Peripheral Nerve Society Meeting | APLT Stock News - GuruFocus
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting - The Manila Times
Applied Therapeutics Presents Full 12-Month Clinical - GlobeNewswire
Breakthrough in CMT Treatment: New Clinical Data Shows First-Ever Disease Progression Slowing in 24-Month Study - Stock Titan
Here's Why Amazon Is a Brilliant Buy Now (Hint: It's Not E-Commerce) - The Globe and Mail
Massive News for Apple Stock Investors! - The Globe and Mail
Applied Therapeutics Inc Stock (APLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Applied Therapeutics Inc Stock (APLT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Funtleyder Leslie D. | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
14,502 |
6,381 |
390,459 |
Chinoporos Constantine | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
447 |
197 |
271,436 |
Funtleyder Leslie D. | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
22,950 |
14,000 |
404,961 |
Perfetti Riccardo | Chief Medical Officer |
Feb 06 '25 |
Sale |
0.61 |
86,078 |
52,508 |
900,775 |
Chinoporos Constantine | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
28,117 |
17,151 |
271,883 |
Funtleyder Leslie D. | Chief Financial Officer |
Aug 22 '24 |
Sale |
5.83 |
13,530 |
78,880 |
277,911 |
Perfetti Riccardo | Chief Medical Officer |
Aug 22 '24 |
Sale |
5.83 |
22,681 |
132,230 |
986,853 |
Shendelman Shoshana | President and CEO |
Aug 13 '24 |
Sale |
6.18 |
357,423 |
2,208,874 |
4,810,430 |
Shendelman Shoshana | President and CEO |
Aug 12 '24 |
Sale |
5.98 |
300,000 |
1,794,000 |
5,167,853 |
Shendelman Shoshana | President and CEO |
Aug 14 '24 |
Sale |
5.93 |
119,591 |
709,175 |
4,690,839 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):